Derivation and Validation of a 4-Level Clinical Pretest Probability Score for Suspected Pulmonary Embolism to Safely Decrease Imaging Testing
| dc.contributor.author | Germeau, Boris | |
| dc.contributor.author | Righini, Marc | |
| dc.contributor.author | Le Gal, Grégoire | |
| dc.contributor.author | Roy, Pierre-Marie | |
| dc.contributor.author | Friou, Emilie | |
| dc.contributor.author | Douillet, Delphine | |
| dc.contributor.author | Kline, Jeffrey A. | |
| dc.contributor.author | Moumneh, Thomas | |
| dc.contributor.author | Penaloza, Andrea | |
| dc.date.accessioned | 2025-06-17T16:13:41Z | |
| dc.date.available | 2025-06-17T16:13:41Z | |
| dc.date.issued | 2021-06-01 | |
| dc.description.abstract | In patients with suspected pulmonary embolism (PE), overuse of diagnostic imaging is an important point of concern.To derive and validate a 4-level pretest probability rule (4-Level Pulmonary Embolism Clinical Probability Score [4PEPS]) that makes it possible to rule out PE solely on clinical criteria and optimized D-dimer measurement to safely decrease imaging testing for suspected PE.This study included consecutive outpatients suspected of having PE from US and European emergency departments. Individual data from 3 merged management studies (n = 11 114; overall prevalence of PE, 11%) were used for the derivation cohort and internal validation cohort. The external validation cohorts were taken from 2 independent studies, the first with a high PE prevalence (n = 1548; prevalence, 21.5%) and the second with a moderate PE prevalence (n = 1669; prevalence, 11.7%). A prior definition of pretest probability target values to achieve a posttest probability less than 2% was used on the basis of the negative likelihood ratios of D-dimer. Data were collected from January 2003 to April 2016, and data were analyzed from June 2018 to August 2019.The rate of PE diagnosed during the initial workup or during follow-up and the rate of imaging testing.Of the 5588 patients in the derivation cohort, 3441 (61.8%) were female, and the mean (SD) age was 52 (18.5) years. The 4PEPS comprises 13 clinical variables scored from -2 to 5. It results in the following strategy: (1) very low probability of PE if 4PEPS is less than 0: PE ruled out without testing; (2) low probability of PE if 4PEPS is 0 to 5: PE ruled out if D-dimer level is less than 1.0 μg/mL; (3) moderate probability of PE if 4PEPS is 6 to 12: PE ruled out if D-dimer level is less than the age-adjusted cutoff value; (4) high probability of PE if 4PEPS is greater than 12: PE ruled out by imaging without preceding D-dimer test. In the first and the second external validation cohorts, the area under the receiver operator characteristic curves were 0.79 (95% CI, 0.76 to 0.82) and 0.78 (95% CI, 0.74 to 0.81), respectively. The false-negative testing rates if the 4PEPS strategy had been applied were 0.71% (95% CI, 0.37 to 1.23) and 0.89% (95% CI, 0.53 to 1.49), respectively. The absolute reductions in imaging testing were -22% (95% CI, -26 to -19) and -19% (95% CI, -22 to -16) in the first and second external validation cohorts, respectively. The 4PEPS strategy compared favorably with all recent strategies in terms of imaging testing.The 4PEPS strategy may lead to a substantial and safe reduction in imaging testing for patients with suspected PE. It should now be tested in a formal outcome study. | |
| dc.description.spage | 669 | |
| dc.description.volume | 6 | |
| dc.identifier.doi | 10.1001/jamacardio.2021.0064 | |
| dc.identifier.handle | 2078.1/261339 | |
| dc.identifier.handle | 1805/29492 | |
| dc.identifier.issn | 2380-6583 | |
| dc.identifier.openaire | doi_dedup___:86f139a78617c216269dd482b2c7217b | |
| dc.identifier.pmc | PMC7931139 | |
| dc.identifier.pmid | 33656522 | |
| dc.identifier.uri | https://ror.circle-u.eu/handle/123456789/805079 | |
| dc.openaire.affiliation | UCLouvain | |
| dc.openaire.collaboration | 1 | |
| dc.publisher | American Medical Association (AMA) | |
| dc.rights | OPEN | |
| dc.source | JAMA Cardiology | |
| dc.subject | Male | |
| dc.subject | Medical Overuse | |
| dc.subject | Fibrin Fibrinogen Degradation Products | |
| dc.subject | Predictive Value of Tests | |
| dc.subject | info:eu-repo/classification/ddc/616 | |
| dc.subject | Predictive value of tests | |
| dc.subject | Biomarkers / blood | |
| dc.subject | Humans | |
| dc.subject | Original Investigation | |
| dc.subject | Aged | |
| dc.subject | Aged, 80 and over | |
| dc.subject | Medical overuse | |
| dc.subject | Pulmonary embolism | |
| dc.subject | Fibrin fibrinogen degradation products | |
| dc.subject | Hospital emergency service | |
| dc.subject | Fibrin Fibrinogen Degradation Products / analysis | |
| dc.subject | Middle Aged | |
| dc.subject | Pulmonary Embolism / diagnosis | |
| dc.subject | Female | |
| dc.subject | Emergency Service, Hospital | |
| dc.subject | Pulmonary Embolism | |
| dc.subject | Biomarkers | |
| dc.subject.fos | 03 medical and health sciences | |
| dc.subject.fos | 0302 clinical medicine | |
| dc.subject.sdg | 3. Good health | |
| dc.title | Derivation and Validation of a 4-Level Clinical Pretest Probability Score for Suspected Pulmonary Embolism to Safely Decrease Imaging Testing | |
| dc.type | publication |